MedTrace Logo

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

NCT00495547 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-04-07

No results posted yet for this study

Summary

The primary objective is to evaluate the efficacy of the treatment in response rate terms. Otherwise this study wants to evaluate the safety of the treatment.

Conditions

Interventions

DRUG

Azacitidine

Azacitidine

DRUG

Beta Erythropoietin

Beta Erythropoietin

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Celgene Corporation

    collaborator INDUSTRY

  • PETHEMA Foundation

    lead OTHER

Principal Investigators

  • Sanz Guillermo, Dr · Hospital La Fe

  • Del Cañizo Consuelo, DR · Hospital Clinico de Salamanca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00495547 on ClinicalTrials.gov